Therapeutic Discovery for Lyme Disease

CHRONIC LYME DISEASE: Borrelia burgdorferi persistent infection with biofilm formation, neurological involvement (neuroborreliosis), joint inflammation (Lyme arthritis), chronic fatigue, cognitive dysfunction ("brain fog"), post-treatment Lyme disease syndrome (PTLDS), antibiotic resistance mechanisms. PATHOGEN CHARACTERISTICS: Spirochete morphology with corkscrew motility, ability to form cystic/round body forms under stress, biofilm matrix production for immune evasion, intracellular persistence in fibroblasts and neurons, collagen tissue tropism, blood-brain barrier penetration. TREATMENT CHALLENGES: Persister cell populations tolerant to antibiotics, biofilm-mediated antibiotic resistance, immune system evasion through antigenic variation, deep tissue reservoirs inaccessible to standard antibiotics, co-infections (Babesia, Bartonella, Ehrlichia).

BORRELIA BURGDORFERI ELIMINATION: Spirochete membrane disruption, biofilm matrix penetration and degradation, cyst form eradication, intracellular persistence clearance, collagen tissue reservoir elimination, blood-brain barrier penetrating agents, immune system evasion countermeasures. TARGET MECHANISMS: Bacterial membrane destabilization, extracellular matrix degradation, metabolic pathway disruption in dormant forms, reactive oxygen species generation within biofilm, quorum sensing interference, metal ion chelation disrupting enzyme function.

BORRELIA BURGDORFERI SPIROCHETE: Cystic forms (round bodies), biofilm matrix, persister cells, immune evasion mechanisms, intracellular survival, blood-brain barrier crossing, collagen tissue affinity, oxidative stress vulnerability. DESIRED PROPERTIES: Biofilm penetration, membrane disruption, immune modulation, anti-inflammatory activity, neuroprotection, minimal toxicity, oral bioavailability, synergy with conventional antibiotics.

DISULFIRAM (ANTABUSE): Dithiocarbamate compound, aldehyde dehydrogenase inhibitor, metal ion chelation (copper, zinc), crosses blood-brain barrier, intracellular accumulation, oxidative stress induction, disrupts bacterial biofilm integrity. KNOWN PROPERTIES: FDA-approved for alcoholism, repurposed antimicrobial activity, demonstrated efficacy against Borrelia in vitro, clinical reports of improvement in chronic Lyme patients, mechanism of anti-Borrelia action unknown. QUESTION: Which mechanism best explains disulfiram's activity against Borrelia burgdorferi?